Individualized toxicity assessments have been completed by various groups as Choi et al. used patient-specific cell lines for individuals deficient in the alpha-1 antitrypsin (A1AT), a protease inhibitor that when absent has been correlated with liver cirrhosis and heptocellular carcinoma [203]. The gene discussed is SERPINA1; the disease is cirrhosis of liver.